6

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

ALLERGAN, INC., AND ALLERGAN SALES, INC. Plaintiff, v. ALCON, INC. ALCON LABORATORIES, INC., AND ALCON RESEARCH, LTD. Defendants.	Civil Action No. 04-968 (GMS)

ALLERGAN, INC. AND ALLERGAN SALES, INC. PRELIMINARY LIST OF FACT WITNESSES

Pursuant to paragraph 2(f) of the Court's Scheduling Order, Allergan, Inc. and Allergan Sales, Inc. (collectively, "Allergan") identifies the following witnesses whose fact testimony will be offered at trial:

Gyorgy Ambrus	Allergan, Inc. 2525 Dupont Drive Irvine, CA
Edward Kerslake	15 Woodbridge Street Cambridge, MA
Orest Olejnik	Allergan, Inc. 2525 Dupont Drive Irvine, CA
Scott Whitcup	Allergan, Inc. 2525 Dupont Drive Irvine, CA

Allergan identifies the following witnesses whose fact testimony may be offered at trial:

Amy Batoosingh	Allergan, Inc. 2525 Dupont Drive Irvine, CA
James Burke	Allergan, Inc. 2525 Dupont Drive Irvine, CA

Hardik Shah	Flat 0/1, 51 Saint Mungo Avenue, Townhead Glasgow G4, 0PL Scotland, UK

In addition, Allergan identifies its named expert witnesses to the extent that the topics described in the expert statements of those witnesses require fact testimony. Allergan will offer testimony from the following named expert witnesses:

Thomas K. Mundorf, M.D.	1718 East 4th Street, Suite 806 Charlotte, NC
Dr. Valentino Stella	1135 West Campus Road Lawrence, KS
Clive G. Wilson	41 Briarcrost Place Robroyston Glasgow G33, 1RF Scotland, UK

Allergan also reserves the right to call at trial any witnesses identified by the Defendants on their witness list.

Dated: January 17, 2006

7

TAB 7

LIST OF POTENTIAL FACT WITNESSES FOR ALCON

Alcon Inc., Alcon Laboratories, Inc. and Alcon Research Ltd. ("Alcon") hereby identify the following witnesses whose fact testimony will be offered at trial:

Ramon Espino	Alcon, Inc. 6201 South Freeway Forth Worth, Texas
Stella Robertson, Ph.D.	Alcon, Inc. 6201 South Freeway Forth Worth, Texas

Alcon hereby identifies the following witnesses whose fact testimony may be offered at trial:

Angelika Aswad	Allergan, Inc. 2525 Dupont Drive Irvine, CA
Ramachandran Chandrasekharan, Ph.D.	4448 Swiss Stone Lane East Apartment 2B Ypsilanti, Michigan
Richard Graham, Ph.D.	Allergan, Inc. 2525 Dupont Drive Irvine, CA
Teresa McClendon	Alcon, Inc. 6201 South Freeway Forth Worth, TX
Angel Padilla	Advanced Medical Optics (AMO) 1700 E. St. Andrew Place Santa Ana, CA

In addition, Alcon identifies its named experts witnesses to the extent that topics discussed in the expert statements of those witnesses require fact testimony. Alcon will offer testimony from:

Gordon Amidon, Ph.D.	2012 College of Pharmacy The University of Michigan Ann Arbor, Michigan

Alcon may offer testimony from:

Alan Robin, M.D.	6115 Falls Road Baltimore, Maryland

Alcon reserves the right to call at trial any witness identified by the Plaintiffs on their witness list. Alcon also reserves the right to question, as an adverse witness, any individual called to testify by the Plaintiffs on matters beyond the scope of direct testimony.

8

Tab 8

ALLERGAN'S STATEMENT REGARDING THE QUALIFICATIONS OF ITS EXPERT WITNESSES

Regarding Valentino Stella, Ph.D.:

Dr. Stella is currently a University Distinguished Professor of Pharmaceutical Chemistry at the University of Kansas where he teaches courses in pharmacokinetics and drug stability. Dr. Stella has an undergraduate degree in pharmacy from the Victorian College of Pharmacy in Melbourne, Australia and practiced as a pharmacist for one year prior to entering graduate school in 1968. He has a doctorate in Analytical Pharmaceutical Chemistry and Pharmaceutics from the University of Kansas that he received in 1971. Dr. Stella was then was an Assistant Professor at the University of Illinois Medical Center in Chicago before returning to the University of Kansas. During his time at the University of Kansas, he was the Director for the Center of Drug Delivery Research from 1989 to 1999. Dr. Stella has also been a consultant to the pharmaceutical industry, both to innovator and to generic companies, since 1972.

Dr. Stella's Curriculum Vitae is incorporated herein by reference.

Regarding Thomas K. Mundorf, M.D.:

Dr. Mundorf received his undergraduate degree from Wake Forest University in 1973. He graduated from Bowman Gray School of Medicine in Winston-Salem, North Carolina in 1982. Dr. Mundorf was an Intern and Resident in Ophthalmology at the North Carolina Baptist Hospital in Winston-Salem, North Carolina, from 1982 to 1986. He was a Fellow in Glaucoma under Thom Zimmerman, M.D., Ph.D., at the University of Louisville from 1986 to 1987.

Dr. Mundorf began his private practice in Charlotte, North Carolina in 1987, specializing in the treatment of glaucoma. Approximately 70% of his practice is directed at treating patients with

glaucoma. Dr. Mundorf sees and treats approximately 400 glaucoma patients each month in his practice. He is a member of the American Academy of Ophthalmology, North Carolina Society of Eye Physicians and Surgeons, and the Association for Research in Vision and Ophthalmology.

Dr. Mundorf has authored or co-authored approximately 20 peer-reviewed publications. He wrote a chapter entitled "Normal Tension Glaucoma" that was published in Clinical Pathways in Glaucoma, T. Zimmerman (ed.), 2001. He has lectured on the subjects of ophthalmology and glaucoma treatment more than 250 times in the U.S., Canada, Central America, South America, South Korea, Vietnam and Malaysia.

At present, Dr. Mundorf is not a consultant to any pharmaceutical company. Since 1986, he has participated in at least 75 studies for a variety of pharmaceutical companies including Allergan, Alcon, Merck, Pfizer, Santen and Novartis.

Dr. Mundorf's Curriculum Vitae is incorporated herein by reference.

Regarding Clive G. Wilson, Ph.D.:

Dr. Wilson received his Bachelors of Science in Applied Biology with honors from Hatfield Polytechnic in 1969. In 1973 he received his Ph.D. in Biochemistry, with an emphasis in drug metabolism, from the University of Surrey. Dr. Wilson is currently a Professor and J P Todd Chair of Pharmaceutics at Strathclyde Institute for Biomedical Sciences, University of Strathclyde, in Glasgow, U.K. In addition, he was formerly an Adjunct Professor of Industrial Pharmacy & Pharmaceutics at the College of Pharmacy, University of Cincinnati, in Cincinnati, Ohio, and Chief Scientist at the BioImaging Research Centre, in Glasgow, U.K. Dr. Wilson's research focus is on the study of the behavior of drug dosage formulations in man, particularly following delivery by the

gastrointestinal tract, eye and pulmonary routes. In his career, he has published over 140 peer-reviewed papers and over 400 publications.

Dr. Wilson's Curriculum Vitae is incorporated herein by reference.

9

TAB 9

ALCON'S STATEMENT REGARDING THE QUALIFICATIONS OF ITS EXPERT WITNESSES

Regarding Gordon Amidon, Ph.D.:

Dr. Gordon Amidon is the Charles R. Walgreen, Jr. Professor of Pharmacy and a Professor of Pharmaceutics at the College of Pharmacy at the University of Michigan, in Ann Arbor, where he conducts research and teaches courses in various aspects of pharmacology and pharmaceutical chemistry, including the formulation and properties of drug product solutions. Additionally, for many years Dr. Amidon taught courses in statistics at the University of Wisconsin. He is also the Chairman and Chief Scientific Officer of TSRL, Inc., a biopharmaceutical research company that provides consulting and research services in such areas of pharmaceutical science as drug formulation and delivery. He has over 35 years of experience working on, teaching about, and studying drug formulations and drug delivery, including the design and analysis of experimental studies of drug formulations and their properties.

Dr. Amidon received his B.S. degree in Pharmacy from the State University of New York at Buffalo. His M.A. degree in Mathematics and Ph.D. in Pharmaceutical Chemistry were both from the University of Michigan, at Ann Arbor. He has received a number of honors and awards for his work in pharmaceutical sciences, including the American Association of Pharmaceutical Scientists Meritorious Manuscript Award, the American Association of Colleges of Pharmacy Volwiler Research Achievement Award, and an honorary Doctor of Pharmacy degree from Uppsala University, Uppsala, Sweden.

Dr. Amidon is a member of many professional societies, including the American Association of Pharmaceutical Scientists (of which he was President in 1998), the

American Pharmacists Association, the American Society for Biochemistry & Molecular Biology, the American Chemical Society and the Controlled Release Society. He has served on the editorial board for a number of peer-reviewed publications, including the International Journal of Pharmaceutics, the Journal of Pharmaceutical Sciences, and Pharmaceutical Research. He is also the editor of the Journal of Molecular Pharmaceutics. Dr. Amidon has been an invited lecturer or a symposium participant more than two hundred times, and is an author or co-author of more than 250 papers that have been published in peer-reviewed scientific or medical journals, and approximately thirty book chapters and monographs, including "Drug derivitization as a means of solubilization: Physicochemical and biochemical strategies," in Yalkowsky, Techniques of Solubilization of Drugs (1981); "Solubility, intrinsic dissolution and solubilization: Influence on absorption," in Amidon et al., Scientific Foundations for Regulating Drug Product Quality (1997); and "Solubility as a limiting factor to drug absorption," in Dressman, Methods for Assessing Oral Drug Absorption (2000).

Dr. Amidon has substantial experience teaching biopharmaceutics and pharmaceutical chemistry to undergraduate and graduate students; a number of his graduate and professional courses have focused on solubility issues. For many years Dr. Amidon also taught courses in statistics. Dr. Amidon conducts extensive research in the area of drug formulations and maintains a substantial laboratory for research in that area.

The subject matter of Dr. Amidon's testimony will concern non-infringement and invalidity of the '337 patent, consistent with the opinions and bases therefore as set forth in his expert report, rebuttal report and any errata or supplements thereto.

Additional facts about Dr. Amidon's background and qualifications, including a complete list of publications, are set forth in his curriculum vitae, which is incorporated herein by reference.

Regarding Alan Robin, M.D.:

Dr. Robin is an Associate Professor of Ophthalmology at the School of Medicine at Johns Hopkins University, an Adjunct Associate Professor of International Health at the Bloomberg School of Public Health at Johns Hopkins University, a Clinical Professor of Ophthalmology at the School of Medicine at the University of Maryland, and a Professor of Ophthalmology in the Veterans Administration System, in Baltimore, Maryland. His specialty is ophthalmology and his subspecialty is glaucoma. Throughout the course of his career, Dr. Robin has had approximately 12,000 glaucoma patients under his care. He has consulted for numerous companies that work on both the development of ophthalmic pharmaceuticals and on diagnostic and therapeutic devices, including both Alcon and Allergan.

Dr. Robin received his B.A. degree from Yale University and his M.D. from Tufts University School of Medicine, in Massachusetts. After graduating from medical school, he was an intern at Rochester General Hospital, in Rochester, New York. From 1975 – 1978, he was a Resident, and ultimately the Chief Resident, in Ophthalmology at the Greater Baltimore Medical Center, in Baltimore, Maryland. The following year (1978-79) he was a Postdoctoral Fellow in Glaucoma at the Wilmer Institute of the Johns Hopkins Hospital in Baltimore, Maryland. Dr. Robin is licensed to practice medicine in

New York, Maryland, and Pennsylvania and is certified by the American Board of Ophthalmology.

Dr. Robin has received a number of honors and awards for his work in connection with glaucoma, including the 1998 Senior Honor Award from the American Academy of Ophthalmology and the 1977 Janice Krushner Award from the International Glaucoma Association. He was also recently presented with the Outstanding Humanitarian Service Award for 2005 by the American Ophthalmologic Society.

Dr. Robin is a member of numerous professional societies, including the American Academy of Ophthalmology, the American Ophthalmological Society, and the Association for Research in Vision and Ophthalmology, and is a charter member of the American Glaucoma Society. He has been a member of the Board of the International Eye Foundation and the Maryland Society to Prevent Blindness. He has also been an invited lecturer or a symposium participant approximately one hundred times, mostly in connection with the treatment of glaucoma.

The focus of his research has been the treatment of glaucoma, and he has participated in trials and evaluations of a number of different pharmacologic therapies for glaucoma. Dr. Robin is an author or co-author of more than 150 papers that have been published in peer-reviewed scientific or medical journals, and approximately twenty other book chapters and monographs. He was a clinical investigator for Allergan in a study that evaluated three different concentrations of brimonidine tartrate (0.08%, 0.2%, 0.5%) for potential treatment of patients suffering from glaucoma or elevated intraocular pressure. He is a co-author of the article reporting the findings of that study, Robert J. Derrick, et al., "Brimonidine Tartrate: A One-month Dose Response Study,"

Ophthalmology, 104(1), 131-136 (1997). The 0.2% brimonidine tartrate concentration tested in that reported study was subsequently marketed commercially by Allergan under the trade name Alphagan.

Dr. Robin has taught the medical therapy of glaucoma to ophthalmology residents, ophthalmology fellows, and optometry students and residents for close to two decades. This instruction includes, but is not limited to, concepts of therapy (compliance, formulation, drop size, dose response), aqueous formation, aqueous flow, intraocular pressure measurements, classes of medications, side effects of each, and how to use each. He has lectured and presented data on treatments for glaucoma in Asia, Africa, Australia, and the United States. He also works on public health issues relating to the prevention of blindness in less developed nations.

The subject matter of Dr. Robin's testimony will be limited to invalidity defenses to the '834 patent that will be distinct from those offered by Dr. Amidon and consistent with those set forth in Dr. Robin's report.

Additional facts about Dr. Robin's background and qualifications, including a complete list of publications, are set forth in his curriculum vitae, which is incorporated herein by reference.

10

TAB 10

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
ALLERGAN'S DEPOSITION DESIGNATIONS
January 17, 2006

DEPONENT	DATE	PAGE/LINE RANGE
Haresh Bhagat	September 8, 2005	7:7-11
		10:5-14
		13:24-14:2
		14:14-14:18
		18:9-16
		41:18-23
		42:3-13
		49:9-49:17
		51:3-52:7
		55:21-55:25
		56:3-56:21
		57:1-57:7
		57:20-58:12
		59:4-24
		63:6-24
		64:23-65:2
		70:6-12
		74:20-75:4
		75:25-76:4
		77:8-18
		77:23-78:4
		84:17-85:11
		104:10-105:4
		113:6-116:10
Moji Bonakdar	August 25, 2005	7:17-21
		11:3-12:2
		13:22-14:4
		14:13-15
		14:22-15:2
		19:17-25
		20:13-21:2
		26:14-17
		28:1-29:4
		29:13-30:17
		34:6-35:14
		36:20-38:7
		38:12-40:8
		55:4-56:4
		57:16-58:14
		61:23-63:5
		63:17-21
		64:5-14
		79:24-80:17
		97:22-98:24

TAB 10

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
ALLERGAN'S DEPOSITION DESIGNATIONS
January 17, 2006

DEPONENT	DATE	PAGE/LINE RANGE
		102:25-103:9
		115:10-116:9
David Herrick	August 24, 2005	7:4-8
		8:25-9:5
		11:3-13
		15:13-23
		21:6-7
		21:12-16
		22:7-9
		24:18-21
		26:19-27:4
		38:8-25
		52:24-53:14
		61:8-61:8
		61:10-25
		62:15-63:10
		65:14-20
		71:7-72:6
		74:3-18
		110:17-111:6
		115:3-116:1
Michael Pfleger	August 3, 2005	6:2-5
		17:8-21
		18:23-19:3
		43:23-44:3
		49:16-50:20
		56:1-6
Patrick Ryan	August 4, 2005	7:1-4
		30:6-15
		31:23-32:1
		34:4-12
		36:22-37:6
		39:6-18
		40:24-41:11
		47:3-14
		60:21-25
		61:23-25
		62:13-14
		65:18-66:11
		75:9-17
		77:7-11
		78:2-8
		80:12-15

TAB 10

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
ALLERGAN'S DEPOSITION DESIGNATIONS
January 17, 2006

DEPONENT	DATE	PAGE/LINE RANGE
		84:8-11
		87:1-5
		87:10-13
		87:17-20
Patricia Underwood	April 19, 2005	6:6-9
		8:11-17
		9:3-8
		11:3-11

10587271.doc

10A

TAB 10-A

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S COUNTER DESIGNATIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN COUNTER-DESIGNATION
Angelika Aswad	8:2-15	16:18-17:17
(September 16, 2005)	14:17-15:17	25:17-23
	16:5-17	27:2-4
	18:2-19:6	83:10-14
	19:23-20:23	84:4-9
	21:7-22:21	84:12-14
	29:9-11	84:16-18
	30:9-31:5	87:2-12
	44:4-8	103:4-10
	58:7-22	
	67:18-21	
	80:16-81:25	
	82:17-83:9	
	83:25-84:3	
	86:17-87:1	
	87:13-88:5	
	91:10-92:16	
	92:25-93:15	
	94:3-6	
	101:1-7	
	102:1-103:3	
	105:25-107:4	
	115:4-22	
Richard Graham, Ph.D.	6:14-15	11:5-15
(September 15, 2005)	11:16-12:1	12:2-8
	14:22-16:4	16:6-13
	17:14-18	17:19-18:4
	23:9-20	29:14-20
	24:6-25:13	30:3-16
	29:21-30:2	47:7-14
	38:24-39:5	49:2-6
	41:9-42:9	49:8-24
	43:25-44:12	76:16-77:12
	44:24-47:5	100:11-13
	47:15-20	100:16-18

[Note: Objections have been raised to several of defendant's designations. Should those objections be sustained, plaintiff reserves the right to withdraw its corresponding counter-designations.]

TAB 10-A

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S COUNTER DESIGNATIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN COUNTER-DESIGNATION
	54:21-55:1	100:20-22
	55:15-56:15	104:18-105:1
	58:14-60:14	105:8-15
	75:13-76:15	122:12-24
	100:23-101:15	138:15-18
	104:2-6	140:14-141:5
	105:2-7	144:10-16
	125:22-126:3	144:19-145:6
	126:24-128:3	181:19-182:14
	132:25-133:5	210:3-5
	133:12-21	
	135:18-137:2	
	137:21-138:14	
	138:19-140:2	
	140:9-13	
	141:6-144:9	
	145:8-146:4	
	165:4-18	
	165:24-166:6	
	168:22-169:18	
	174:17-175:3	
	178:24-181:18	
	182:15-183:12	
	197:10-11	
	197:15-198:13	
	198:22-201:22	
	202:11-204:20	
	204:23-207:18	
	207:22-208:14	
	208:17-209:25	
	210:7-212:18	
Carlos A. Fisher	7:12-13	
(July 20, 2005)	14:5-16	
	83:20-23	
	87:19-88:13	
	93:21-94:9	

[Note: Objections have been raised to several of defendant's designations. Should those objections be sustained, plaintiff reserves the right to withdraw its corresponding counter-designations.]

TAB 10-A

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S COUNTER DESIGNATIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN COUNTER-DESIGNATION
	109:25-114:8	
	117:3-119:12	
Edward Kerslake, Ph.D.	6:9-12	13:12-25
(April 28, 2005)	7:12-8:10	14:10-16
	31:2-33:14	15:2-21
	33:22-34:20	16:10-15
	40:8-14	35:22-25
	55:3-59:25	36:2-3
	62:17-63:16	36:8-25
	63:23-66:19	37:2-19
	74:17-23	39:12-25
	77:15-79:8	40:2-5
	83:18-84:22	74:24-25
	87:2-89:11	75:2-5
	95:10-96:24	79:9-21
	101:9-102:9	84:23
	108:11-112:23	89:12-15
	117:6-22	89:18-20
	118:7-11	103:15-25
	121:23-122:24	104:2
	125:18-127:25	104:5-25
	131:4-132:14	117:14-15
	135:8-22	171:23-25
	137:10-19	192:20
	138:7-12	
	139:2-5	
	145:12-15	
	146:20-147:10	
	149:21-151:13	
	156:12-166:19	
	167:4-171:2	
	171:13-21	
	174:23-179:15	
	180:2-21	
	182:11-183:9	
	184:19-185:4	

[Note: Objections have been raised to several of defendant's designations. Should those objections be sustained, plaintiff reserves the right to withdraw its corresponding counter-designations.]

TAB 10-A

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S COUNTER DESIGNATIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN COUNTER-DESIGNATION
	185:20-187:17	
	188:4-16	
	189:7-14	
	192:2-19	
	194:2-7	
Orest Olejnik, Ph.D. (June 23, 2005)	12:10-13:1	20:10-24
	19:17-21	44:22-45:7
	26:13-27:16	50:25
	44:16-21	51:21-24
	46:3-17	87:3-18
	47:12-48:25	91:2-17
	49:11-16	92:6-23
	50:8-18	109:10-19
	50:24-51:20	120:2-23
	55:17-25	143:4-18
	58:1-60:3	150:14-23
	60:14-61:16	151:12-152:7
	64:22-66:21	154:3-7
	87:19-25	155:7-13
	88:6-21	156:5-157:17
	89:1	163:22-164:3
	91:18-92:5	167:3-21
	102:13-25	169:9-16
	103:9-107:1	172:17-173:7
	114:24-116:9	174:10-21
	123:11-124:12	191:13-192:1
	126:3-128:13	199:24-200:10
	131:14-132:7	214:18-215:1
	133:21-134:2	
	135:12-137:23	
	141:7-142:2	
	148:13-150:13	
	150:24-151:11	
	152:8-153:9	
	155:14-156:4	
	157:18-160:13	

[Note: Objections have been raised to several of defendant's designations. Should those objections be sustained, plaintiff reserves the right to withdraw its corresponding counter-designations.]

TAB 10-A

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S COUNTER DESIGNATIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN COUNTER-DESIGNATION
	162:2-4	
	162:16-163:13	
	164:4-165:23	
	168:15-169:8	
	169:17-172:16	
	173:21-174:9	
	175:22-178:13	
	178:22-179:15	
	180:16-183:4	
	189:23-191:1	
	192:2-193:23	
	196:10-199:23	
	203:11-207:23	
	209:23-210:21	
	211:23-214:17	
	215:2-23	
	216:15-217:18	
	218:2-10	
Orest Olejnik, Ph.D. (June 24, 2005)	241:16-242:20	238:15-24
	245:13-246:7	239:1-9
	254:6-257:1	239:12-240:1
	258:20-259:12	240:3-12
	259:22-261:16	243:10-15
	264:16-267:8	253:8-254:6
	271:15-274:4	257:19-21
	274:21-275:13	257:24
	283:15-284:14	258:2-19
	285:23-287:20	259:13-21
	288:3-24	271:7-14
	289:8-295:2	298:22-300:2
	295:24-297:9	301:7-8
	297:19-298:8	301:11-22
	298:14-21	301:24-302:15
	303:18-305:19	343:11-344:7
	306:3-308:20	451:12-452:16
	309:6-311:24	456:19-21

[Note: Objections have been raised to several of defendant's designations. Should those objections be sustained, plaintiff reserves the right to withdraw its corresponding counter-designations.]

TAB 10-A

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S COUNTER DESIGNATIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN COUNTER-DESIGNATION
	312:7-314:17	456:24-25
	314:25-327:16	470:25-471:10
	329:23-331:16	
	332:2-338:3	
	338:21-342:20	
	345:5-346:19	
	350:7-13	
	360:5-22	
	361:16-362:1	
	364:8-16	
	383:11-21	
	384:12-385:5	
	390:2-392:10	
	414:22-416:3	
	430:8-9	
	430:14-16	
	430:21-25	
	431:9-432:20	
	450:24-451:2	
	457:6-10	
	461:13-20	
	470:4-19	
	471:11-23	
	477:11-478:18	
Angel Padilla (August 9, 2005)	11:14-12:3	6:9-7:14
	13:2-5	10:24-11:1
	13:23-14:2	12:4-12
	14:8-18	13:9-22
	16:6-17:22	17:23-18:2
	18:25-27:15	18:16-24
	33:20-34:4	69:20-22
	36:2-38:22	74:18-23
	49:17-50:4	158:12-159:4
	52:25-53:5	160:2-14
	53:13-23	170:18-171:1
	56:25-58:2	

[Note: Objections have been raised to several of defendant's designations. Should those objections be sustained, plaintiff reserves the right to withdraw its corresponding counter-designations.]

TAB 10-A

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S COUNTER DESIGNATIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN COUNTER-DESIGNATION
	60:9-18	
	69:16-19	
	71:20-25	
	73:8-10	
	73:20-74:3	
	75:10-23	
	79:22-80:25	
	92:25-93:7	
	94:15-95:4	
	95:17-96:24	
	113:1-7	
	164:11-166:9	
	166:20-167:10	
	170:6-16	
	181:13-184:25	

10588524.doc

[Note: Objections have been raised to several of defendant's designations. Should those objections be sustained, plaintiff reserves the right to withdraw its corresponding counter-designations.]

10B

TAB 10-B

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S OBJECTIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN OBJECTIONS TO ALCON DESIGNATION
Angelika Aswad	8:2-15	
(September 16, 2005)	14:17-15:17	
	16:5-17	
	18:2-19:6	
	19:23-20:23	
	21:7-22:21	
	29:9-11	
	30:9-31:5	
	44:4-8	
	58:7-22	
	67:18-21	
	80:16-81:25	F.R.E. 602
	82:17-83:9	F.R.E. 602, F.R.E. 802
	83:25-84:3	F.R.E. 802
	86:17-87:1	F.R.E. 802
	87:13-88:5	F.R.E. 602, F.R.E. 802
	91:10-92:16	
	92:25-93:15	
	94:3-6	
	101:1-7	F.R.E. 802
	102:1-103:3	F.R.E. 602, F.R.E. 802
	105:25-107:4	
	115:4-22	F.R.E. 402 & 403
Richard Graham, Ph.D.	6:14-15	
(September 15, 2005)	11:16-12:1	
	14:22-16:4	
	17:14-18	
	23:9-20	
	24:6-25:13	
	29:21-30:2	
	38:24-39:5	F.R.E. 802, F.R.E. 402 & 403
	41:9-42:9	F.R.E. 802, F.R.E. 402 & 403
	43:25-44:12	F.R.E. 802, F.R.E. 402 & 403
	44:24-47:5	F.R.E. 802, F.R.E. 402 & 403
	47:15-20	
	54:21-55:1	F.R.E. 802, F.R.E. 402 & 403
	55:15-56:15	F.R.E. 802, F.R.E. 402 & 403, F.R.E. 602

TAB 10-B

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S OBJECTIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN OBJECTIONS TO ALCON DESIGNATION
	58:14-60:14	F.R.E. 802, F.R.E. 402 & 403
	75:13-76:15	F.R.E. 802, F.R.E. 402 & 403
	100:23-101:15	F.R.E. 802, F.R.E. 402 & 403
	104:2-6	F.R.E. 402 & 403
	105:2-7	F.R.E. 402 & 403
	125:22-126:3	F.R.E. 802, F.R.E. 402 & 403
	126:24-128:3	F.R.E. 802, F.R.E. 402 & 403, F.R.E. 602
	132:25-133:5	
	133:12-21	F.R.E. 802, F.R.E. 402 & 403
	135:18-137:2	F.R.E. 802, F.R.E. 602
	137:21-138:14	F.R.E. 802, F.R.E. 602
	138:19-140:2	F.R.E. 802, F.R.E. 602
	140:9-13	F.R.E. 802, F.R.E. 602
	141:6-144:9	F.R.E. 802, F.R.E. 402 & 403, F.R.E. 602
	145:8-146:4	F.R.E. 802, F.R.E. 402 & 403
	165:4-18	F.R.E. 802, F.R.E. 402 & 403
	165:24-166:6	F.R.E. 802, F.R.E. 402 & 403
	168:22-169:18	F.R.E. 802, F.R.E. 402 & 403
	174:17-175:3	F.R.E. 402 & 403
	178:24-181:18	F.R.E. 802, F.R.E. 402 & 403
	182:15-183:12	F.R.E. 802, F.R.E. 402 & 403
	197:10-11	F.R.E. 802
	197:15-198:13	F.R.E. 802, F.R.E. 402 & 403
	198:22-201:22	F.R.E. 802, F.R.E. 402 & 403, F.R.E. 602
	202:11-204:20	F.R.E. 802, F.R.E. 402 & 403
	204:23-207:18	F.R.E. 802, F.R.E. 402 & 403
	207:22-208:14	F.R.E. 802, F.R.E. 402 & 403, F.R.E. 602
	208:17-209:25	F.R.E. 802, F.R.E. 402 & 403, F.R.E. 602
	210:7-212:18	F.R.E. 802, F.R.E. 402 & 403, F.R.E. 602
Carlos A. Fisher (July 20, 2005)	7:12-13	
	14:5-16	
	83:20-23	F.R.E. 402 & 403
	87:19-88:13	F.R.E. 402 & 403

TAB 10-B

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S OBJECTIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN OBJECTIONS TO ALCON DESIGNATION
	93:21-94:9	F.R.E. 402 & 403
	109:25-114:8	F.R.E. 402 & 403
	117:3-119:12	F.R.E. 402 & 403, F.R.E. 602, F.R.E. 802
Edward Kerslake, Ph.D.	6:9-12	
(April 28, 2005)	7:12-8:10	
	31:2-33:14	
	33:22-34:20	
	40:8-14	
	55:3-59:25	Up to 59:16: F.R.E. 402 & 403, F.R.E. 602, F.R.E. 802
	62:17-63:16	F.R.E. 402 & 403, F.R.E. 602, F.R.E. 802
	63:23-66:19	F.R.E. 402 & 403, F.R.E. 602, F.R.E. 802
	74:17-23	
	77:15-79:8	
	83:18-84:22	84:8-22: F.R.E. 602, F.R.E. 402 & 403
	87:2-89:11	F.R.E. 402 & 403, F.R.E. 802, F.R.E. 602
	95:10-96:24	F.R.E. 402 & 403
	101:9-102:9	102:4-9: F.R.E. 602
	108:11-112:23	111:14-112:13: F.R.E. 602, F.R.E. 802
	117:6-22	F.R.E. 402 & 403
	118:7-11	F.R.E. 402 & 403, F.R.E. 802
	121:23-122:24	F.R.E. 402 & 403, F.R.E. 802
	125:18-127:25	126:24-127:25: F.R.E. 802
	131:4-132:14	
	135:8-22	
	137:10-19	
	138:7-12	
	139:2-5	
	145:12-15	
	146:20-147:10	
	149:21-151:13	
	156:12-166:19	156:25-157:8: F.R.E. 602
	167:4-171:2	168:6-23: F.R.E. 402 & 403
	171:13-21	

TAB 10-B

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S OBJECTIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN OBJECTIONS TO ALCON DESIGNATION
	174:23-179:15	
	180:2-21	180:14-21: F.R.E. 802, F.R.E. 402 & 403, F.R.E. 602
	182:11-183:9	
	184:19-185:4	185:1-4: F.R.E. 602
	185:20-187:17	186:10-187:17: F.R.E. 602
	188:4-16	F.R.E. 602
	189:7-14	F.R.E. 402 & 403, F.R.E. 602
	192:2-19	
	194:2-7	
Orest Olejnik, Ph.D. (June 23, 2005)	12:10-13:1	
	19:17-21	
	26:13-27:16	
	44:16-21	
	46:3-17	
	47:12-48:25	
	49:11-16	
	50:8-18	
	50:24-51:20	F.R.E. 402 & 403
	55:17-25	F.R.E. 602
	58:1-60:3	58:1-9: F.R.E. 402 & 403
	60:14-61:16	60:22-61:4: F.R.E. 602
	64:22-66:21	F.R.E. 402 & 403
	87:19-25	F.R.E. 402 & 403
	88:6-21	F.R.E. 402 & 403
	89:1	F.R.E. 402 & 403
	91:18-92:5	
	102:13-25	F.R.E. 402 & 403
	103:9-107:1	F.R.E. 402 & 403
	114:24-116:9	
	123:11-124:12	F.R.E. 402 & 403, F.R.E. 602
	126:3-128:13	F.R.E. 402 & 403
	131:14-132:7	F.R.E. 402 & 403, F.R.E. 802
	133:21-134:2	F.R.E. 402 & 403, F.R.E. 802
	135:12-137:23	F.R.E. 402 & 403, F.R.E. 802
	141:7-142:2	
	148:13-150:13	
	150:24-151:11	
	152:8-153:9	F.R.E. 402 & 403, F.R.E. 802

TAB 10-B

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S OBJECTIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN OBJECTIONS TO ALCON DESIGNATION
	155:14-156:4	F.R.E. 402 & 403, F.R.E. 802
	157:18-160:13	157:18-159:10: F.R.E. 402 & 403, F.R.E. 802
	162:2-4	
	162:16-163:13	
	164:4-165:23	
	168:15-169:8	
	169:17-172:16	
	173:21-174:9	
	175:22-178:13	177:8-178:13: F.R.E. 402 & 403, F.R.E. 602
	178:22-179:15	F.R.E. 402 & 403
	180:16-183:4	F.R.E. 402 & 403
	189:23-191:1	
	192:2-193:23	192:2-193:14: F.R.E. 402 & 403, F.R.E. 602
	196:10-199:23	
	203:11-207:23	
	209:23-210:21	209:23-210:14: F.R.E. 802
	211:23-214:17	211:23-212:21: F.R.E. 802
	215:2-23	
	216:15-217:18	
	218:2-10	
Orest Olejnik, Ph.D. (June 24, 2005)	241:16-242:20	
	245:13-246:7	F.R.E. 402 & 403
	254:6-257:1	255:2-257:1: F.R.E. 602
	258:20-259:12	F.R.E. 602
	259:22-261:16	259:22-260:1: F.R.E. 602
	264:16-267:8	
	271:15-274:4	
	274:21-275:13	F.R.E. 602, F.R.E. 802
	283:15-284:14	F.R.E. 602
	285:23-287:20	F.R.E. 402 & 403, F.R.E. 802
	288:3-24	F.R.E. 402 & 403, F.R.E. 802
	289:8-295:2	289:23-295:2: F.R.E. 602; 289:8-22: F.R.E. 802, F.R.E. 402 & 403
	295:24-297:9	F.R.E. 402 & 403, F.R.E. 802
	297:19-298:8	F.R.E. 402 & 403, F.R.E. 802

TAB 10-B

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S OBJECTIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN OBJECTIONS TO ALCON DESIGNATION
	298:14-21	F.R.E. 402 & 403
	303:18-305:19	
	306:3-308:20	F.R.E. 802, F.R.E. 402 & 403; 307:24-308:20: F.R.E. 602
	309:6-311:24	F.R.E. 802, F.R.E. 402 & 403
	312:7-314:17	F.R.E. 802, F.R.E. 402 & 403
	314:25-327:16	F.R.E. 402 & 403, F.R.E. 602; 314:25-321:16: F.R.E. 802
	329:23-331:16	F.R.E. 602, F.R.E. 402 & 403
	332:2-338:3	F.R.E. 402 & 403, F.R.E. 602, F.R.E. 802
	338:21-342:20	F.R.E. 402 & 403, F.R.E. 602, F.R.E. 802
	345:5-346:19	F.R.E. 402 & 403
	350:7-13	F.R.E. 402 & 403
	360:5-22	F.R.E. 802, F.R.E. 602
	361:16-362:1	F.R.E. 602
	364:8-16	
	383:11-21	F.R.E. 802
	384:12-385:5	F.R.E. 802
	390:2-392:10	F.R.E. 802
	414:22-416:3	
	430:8-9	F.R.E. 802
	430:14-16	F.R.E. 802
	430:21-25	F.R.E. 802
	431:9-432:20	F.R.E. 802
	450:24-451:2	F.R.E. 802
	457:6-10	
	461:13-20	
	470:4-19	F.R.E. 602
	471:11-23	F.R.E. 602
	477:11-478:18	F.R.E. 602
Angel Padilla (August 9, 2005)	11:14-12:3	
	13:2-5	
	13:23-14:2	
	14:8-18	
	16:6-17:22	
	18:25-27:15	
	33:20-34:4	

TAB 10-B

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN'S OBJECTIONS TO
ALCON, INC.'S DEPOSITION DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON DESIGNATION	ALLERGAN OBJECTIONS TO ALCON DESIGNATION
	36:2-38:22	F.R.E. 402 & 403
	49:17-50:4	F.R.E. 402 & 403, F.R.E. 802
	52:25-53:5	F.R.E. 402 & 403
	53:13-23	F.R.E. 402 & 403
	56:25-58:2	F.R.E. 402 & 403
	60:9-18	F.R.E. 402 & 403, F.R.E. 802
	69:16-19	
	71:20-25	
	73:8-10	
	73:20-74:3	73:20-74:3: F.R.E. 402 & 403; 74:1-3: F.R.E. 602
	75:10-23	
	79:22-80:25	79:22-80:25: F.R.E. 402 & 403; 80:18-25: F.R.E. 802 & 602
	92:25-93:7	
	94:15-95:4	F.R.E. 402 & 403, F.R.E. 802
	95:17-96:24	95:23-96:5: F.R.E. 602; 95:17-96:19: F.R.E. 802
	113:1-7	
	164:11-166:9	F.R.E. 602
	166:20-167:10	F.R.E. 802
	170:6-16	F.R.E. 802, F.R.E. 602
	181:13-184:25	F.R.E. 402 & 403, F.R.E. 602 & 802

10588533.doc

10C

TAB 10-C

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS

ALLERGAN OBJECTIONS TO ALCON COUNTER-DESIGNATIONS

January 17, 2006

DEPONENT (DATE OF DEPO)	ALCON COUNTER-DESIGNATION	ALLERGAN OBJECTION TO ALCON COUNTER-DESIGNATION
Haresh Bhagat (September 8, 2005)	78:8-14	
	78:21-79:8	
Moji Bonakdar (August 25, 2005)	35:15-36:14	
	46:7-8	
	50:6-51:13	
	52:2-53:24	
	64:15-65:5	
	66:4-66:13	
	67:1-12	
	117:15-118:20	
	118:25-119:12	
	119:15-20	
David Herrick (August 24, 2005)	53:15-16	
	53:20-23	
	81:10-12	
	114:11-18	
Michael Pfleger (August 3, 2005)	16:23-17:7	
	17:22-18:22	17:22-18:2, 18:5, 18:8-9, 18:12-20: Not Testimony - Objections of Counsel
	19:4-9	
	42:8-43:22	42:15-43:12: Not Testimony - Objections of Counsel
	55:3-25	55:12-18: Not Testimony - Objections of Counsel
	56:7-57:11	
Patrick Ryan (August 4, 2005)	None	
Patricia Underwood (April 19, 2005)	None	

10588859 - Tab 10C.doc

11

TAB 11

ALCON'S OBJECTIONS AND COUNTER-DESIGNATIONS TO ALLERGAN'S DEPOSITION DESIGNATIONS; ALCON'S DEPOSITION DESIGNATIONS AND OBJECTIONS TO ALLERGAN'S COUNTER-DESIGNATIONS

Pursuant to Fed. R. Civ. P. 26(a)(3) and the Court's Scheduling Order, Alcon submits the following designations of deposition testimony, objections to Allergan's counter-designations of deposition testimony, objections to Allergan's designations of deposition testimony, and counter-designations to Allergan's designations of deposition testimony.

Alcon generally objects to Allergan's deposition designations as follows:

1. To the extent Allergan's deposition designations refer to or incorporate exhibits that are listed on Allergan's trial exhibit list, Alcon objects to the use of these exhibits for the reasons set forth in its objections to Allergan's trial exhibits, which objections are hereby incorporated by reference. For brevity, Alcon will not repeat these objections herein.

2. Allergan has designated, or covered, may issues with multiple witnesses. Depending upon whose testimony Allergan tries to use at trial, Alcon also objects on the grounds that the testimony is cumulative.

3. Alcon reserves the right to amend or supplement its objections based on the outcome of any motions decided by the Court before or during trial.

To the extent that Alcon has sought to exclude certain testimony in its motions *in limine*, Alcon has nonetheless made conditional counter-designations in the event that the Court denies Alcon's motions.

Alcon's Key to Objections to Deposition Designations

Abbreviation	Objection
AMBIG	Question is improperly vague and ambiguous
ARG	Question is improperly argumentative
COMP	Compound question; it cannot be determined to which portion of the question the deponent answered or responded
EXP	Question improperly calls for an expert opinion
FO	No foundation; question is premised upon facts that cannot be proven
H	Testimony is hearsay (or hearsay within hearsay) and inadmissible under Fed. R. Evid. 801 and 802 or 805
INC	Designation is incomplete, omitting either part of the question, all or part of the answer, or both
LAW	Testimony as to matters of law
MIST	Question misstates the record
PK	No foundation; it was not established that the witness had any personal knowledge of the subject matter
REL	Testimony is irrelevant and inadmissible under Fed. R. Evid. 402
SP	Question improperly calls for speculation

Haresh Bhagat, September 8, 2005

Allergan Designations	Alcon Objections	Alcon Counters
7:7-11		
10:5-14		
13:24-14:2		
14:14-14:18		
18:9-16		
41:18-23		
42:3-13	AMBIG	
49:9-49:17		
51:3-52:7		
55:21-55:25	MIST & COMP	
56:3-56:21	MIST & COMP (as to 56:3-4)	
57:1-57:7		
57:20-58:12	AMBIG (as to 57:20-58:1)	
59:4-24		
63:6-24	COMP (as to 63:6-14)	
64:23-65:2	REL	
70:6-12	FO	
74:20-75:4		
75:25-76:4		
77:8-18	REL	78:8-14 78:21-79:8
77:23-78:4	REL	
84:17-85:11		
104:10-105:4	FO (as to 104:10-20)	
113:6-116:10	AMBIG (as to 112:6-15)	

Moji Bonakdar, August 25, 2005

Allergan Designations	Alcon Objections	Alcon Counters
7:17-21		
11:3-12:2		
13:22-14:4		
14:13-15		
14:22-15:2		
19:17-25		
20:13-21:2		
26:14-17		

Allergan Designations	Alcon Objections	Alcon Counters
28:1-29:4		
29:13-30:17	MIST (as to 30:1-3)	
34:6-35:14		35:15-36:14
36:20-38:7		
38:12-40:8	AMBIG (as to 38:15-39:5)	46:7-8 50:6-51:13 52:2-53:24
55:4-56:4		
57:16-58:14		
61:23-63:5	MIST & ARG (as to 62:14-18 and as to 62:19-62:22); FO (as to 62:23-63:1)	
63:17-21	MIST	
64:5-14		64:15-65:5 66:4-66:13 67:1-12
79:24-80:17		
97:22-98:24		
102:25-103:9		
115:10-116:9		117:15-118:20 118:25-119:12 119:15-20

David Herrick, August 24, 2005

Allergan Designations	Alcon Objections	Alcon Counters
7:4-8		
8:25-9:5		
11:3-13		
15:13-23		
21:6-7	REL	
21:12-16	REL	
22:7-9	REL	
24:18-21		
26:19-27:4	REL	
38:8-25		
52:24-53:14	REL & FO (as to 52:24-53:6)	53:15-16 53:20-23
61:8-61:8		
61:10-25	MIST & AMBIG (as to 61:22-25)	

Allergan Designations	Alcon Objections	Alcon Counters
62:15-63:10	MIST & AMBIG (as to 62:15-18)	
65:14-20		
71:7-72:6	REL; AMBIG (as to 71:10-15)	
74:3-18	REL; FO & AMBIG (as to 74:3-8)	81:10-12
110:17-111:6	REL	114:11-18
115:3-116:1	REL; COMP & AMBIG (as to 115:3-8); AMBIG (as to 115:18-23)	

Michael Pfleger, August 3, 2005

Allergan Designations	Alcon Objections	Alcon Counters
6:2-5		
17:8-21	REL	16:2317:7 17:22-18:22 19:4-9
18:23-19:3	REL	
43:23-44:3		42:8-43:22
49:16-50:20		
56:1-6		55:3-25 56:7-57:11

Patricia Underwood, April 19, 2005

Allergan Designations	Alcon Objections	Alcon Counters
6:6-9		
8:11-17		
9:3-8		
11:3-11		

Patrick Ryan, August 4, 2005

Allergan Designations	Alcon Objections	Alcon Counters
7:1-4		
30:6-15		

Allergan Designations	Alcon Objections	Alcon Counters
31:23-32:1		
34:4-12		
36:22-37:6	AMBIG (as to 37:2-6)	
39:6-18	ARG (as to 39:15-18); H (as to 39:18)	
40:24-41:11		
47:3-14	H (as to 47:3-8)	
60:21-25		
61:23-25		
62:13-14		
65:18-66:11	H	
75:9-17		
77:7-11		
78:2-8		
80:12-15		
84:8-11		
87:1-5		
87:10-13		
87:17-20		

Angelika Aswad, September 16, 2005

Alcon Designations	**Allergan Counters**	**Alcon Objects**
8:2-15	16:18-17:17	H
14:17-15:17	25:17-23	
16:5-17	27:2-4	
18:2-19:6	83:10-14	
19:23-20:23	84:4-9	
21:7-22:21	84:12-14	
29:9-11	84:16-18	
30:9-31:5	87:2-12	
44:4-8	103:4-10	
58:7-22		
67:18-21		
80:16-81:25		
82:17-83:9		
83:25-84:3		
86:17-87:1		
87:13-88:5		
91:10-92:16		
92:25-93:15		
94:3-6		

101:1-7		
102:1-103:3		
105:25-107:4		
115:4-22		

Richard Graham, Ph.D., September 15, 2005

Alcon Designations	Allergan Counters	Alcon Objects
6:14-15	11:5-15	
11:16-12:1	12:2-8	REL
14:22-16:4	16:6-13	
17:14-18	17:19-18:4	
23:9-20	29:14-20	
24:6-25:13	30:3-16	
29:21-30:2	47:7-14	
38:24-39:5	49:2-6	
41:9-42:9	49:8-24	
43:25-44:12	76:16-77:12	
44:24-47:5	100:11-13	
47:15-20	100:16-18	
54:21-55:1	100:20-22	
55:15-56:15	104:18-105:1	
58:14-60:14	105:8-15	
75:13-76:15	122:12-24	
100:23-101:15	138:15-18	
104:2-104:6	140:14-141:5	
105:2-7	144:10-16	H
125:22-126:3	144:19-145:6	H
126:24-128:3	181:19-182:14	
132:25-133:5	210:3-5	INC
133:12-21		
135:18-137:2		
137:21-138:14		
138:19-140:2		
140:9-13		
141:6-144:9		
145:8-146:4		
165:4-18		
165:24-166:6		
168:22-169:18		
174:17-175:3		
178:24-181:18		
182:15-183:12		
197:10-11		

197:15-198:13		
198:22-201:22		
202:11-204:20		
204:23-207:18		
207:22-208:14		
208:17-209:25		
210:7-212:18		

Carlos A. Fisher, July 20, 2005

Alcon Designations	Allergan Counters	Alcon Objects
7:12-13		
14:5-16		
83:20-23		
87:19-88:13		
93:21-94:9		
109:25-114:8		
117:3-119:12		

Edward D. S. Kerslake, Ph.D., April 28, 2005

Alcon Designations	Allergan Counters	Alcon Objects
6:9-12	13:12-25	
7:12-8:10	14:10-16	
31:2-33:14	15:2-21	
33:22-34:20	16:10-15	
40:8-14	35:22-25	
55:3-59:25	36:2-3	
62:17-63:16	36:8-25	
63:23-66:9	37:2-19	
74:17-23	39:12-25	
77:15-79:8	40:2-5	
83:18-84:22	74:24-25	
87:2-89:11	75:2-5	
95:10-96:24	79:9-21	
101:9-102:9	84:23	
108:11-112:23	89:12-15	H
117:6-22	89:18-20	H
118:7-11	103:15-25	
121:23-122:24	104:2	
125:18-127:25	104:5-25	
131:4-132:14	117:14-15	
135:8-22	171:23-25	

137:10-19	192:20	
138:7-12		
139:2-5		
145:12-15		
146:20-147:10		
149:21-151:13		
156:12-166:19		
167:4-171:2		
171:13-21		
174:23-179:15		
180:2-21		
182:11-183:9		
184:19-185:4		
185:20-187:17		
188:4-16		
189:7-14		
192:2-19		
194:2-7		

Orest Olejnik, Ph.D, June 23, 2005

Alcon Designations	Allergan Counters	Alcon Objects
12:10-13:1	20:10-24	
19:17-21	44:22-45:7	
26:13-27:16	50:25	
44:16-21	51:21-24	
46:3-17	87:3-18	
47:12-48:25	91:2-17	
49:11-16	92:6-23	
50:8-18	109:10-19	
50:24-51:20	120:2-23	
55:17-25	143:4-18	
58:1-60:3	150:14-23	SP (as to 150:16-23)
60:14-61:16	151:12-152:7	SP (as to 151:12-18)
64:22-66:21	154:3-7	
87:19-25	155:7-13	
88:6-21	156:5-157:17	
89:1	163:22-164:3	
91:18-92:5	167:3-21	
102:13-25	169:9-16	
103:9-107:1	172:17-173:7	
114:24-116:9	174:10-21	
123:11-124:12	191:13-192:1	
126:3-128:13	199:24-200:10	

131:14-132:7	214:18-215:1	
133:21-134:2		
135:12-137:23		
141:7-142:2		
148:13-150:13		
150:24-151:11		
152:8-153:9		
155:14-156:4		
157:18-160:13		
162:2-4		
162:16-163:13		
164:4-165:23		
168:15-169:8		
169:17-172:16		
173:21-174:9		
175:22-178:13		
178:22-179:15		
180:16-183:4		
189:23-191:1		
192:2-193:23		
196:10-199:23		
203:11-207:23		
209:23-210:21		
211:23-214:17		
215:2-23		
216:15-217:18		
218:2-10		

Angel Padilla, August 9, 2005

Alcon Designations	Allergan Counters	Alcon Objects
11:14-12:3	6:9-7:14	
13:2-5	10:24-11:1	
13:23-14:2	12:4-12	
14:8-18	13:9-22	
16:6-17:22	17:23-18:2	
18:25-27:15	18:16-24	
33:20-34:4	69:20-22	
36:2-38:22	74:18-23	
49:17-50:4	158:12-159:4	
52:25-53:5	160:2-14	
53:13-23	170:18-171:1	
56:25-58:2		
60:9-18		
69:16-19		

71:20-25		
73:8-10		
73:20-74:3		
75:10-23		
79:22-80:25		
92:25-93:7		
94:15-95:4		
95:17-96:24		
113:1-7		
164:11-166:9		
166:20-167:10		
170:6-16		
181:13-184:25		

Orest Olejnik, Ph. D, June 24, 2005

Alcon Designations	Allergan Counters	Alcon Objects
241:16-242:20	238:15-24	
245:13-246:7	239:1-9	
254:6-257:1	239:12-240:1	
258:20-259:12	240:3-12	
259:22-261:16	243:10-15	REL
264:16-267:8	253:8-254:6	
271:15-274:4	257:19-21	
274:21-275:13	257:24	
283:15-284:14	258:2-19	
285:23-287:20	259:13-21	
288:3-24	271:7-14	
289:8-295:2	298:22-300:2	
295:24-297:9	301:7-8	
297:19-298:8	301:11-22	
298:14-21	301:24-302:15	
303:18-305:19	343:11-344:7	
306:3-308:20	451:12-452:16	
309:6-311:24	456:19-21	
312:7-314:17	456:24-25	
314:25-327:16	470:25-471:10	
329:23-331:16		
332:2-338:3		
338:21-342:20		
345:5-346:19		
350:7-13		
360:5-22		
361:16-362:1		

364:8-16		
383:11-21		
384:12-385:5		
390:2-392:10		
414:22-416:3		
430:8-9		
430:14-16		
430:21-25		
431:9-432:20		
450:24-451:2		
457:6-10		
461:13-20		
470:4-19		
471:11-23		
477:11-478:18		